Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2021 | Management of patients with relapsed Hodgkin lymphoma

Michael Bishop, MD, University of Chicago, Chicago, IL, explains the different strategies used to treat patients with Hodgkin lymphoma who relapse after autologous stem cell transplantation. Although most patients are sensitive to immunotherapy, many will relapse, and a small number of patients do not respond to checkpoint inhibitors. Upon progression, patients generally undergo allogeneic transplant. Prof. Bishop explains that most patients will have a first-degree relative as an available haploidentical donor, but that it may be harder to find a matched sibling donor or a fully matched unrelated donor. Prof. Bishop reports that existing data indicates that in these cases haploidentical transplants may be preferred. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.